A matrine-type alkaloid, its preparation method, and its application in the preparation of antibacterial synergists.
By preparing novel matrine-type alkaloids SF-34 and SF-60, the problems of drug resistance and insufficient activity of existing antibacterial drugs were solved, and a synergistic antibacterial effect with polymyxin antibiotics was achieved, especially a highly effective antibacterial effect against Escherichia coli.
Patent Information
- Application Number
- CN202611120751.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2026-07-27
- Publication Date
- 2026-11-17
AI Technical Summary
Existing antibacterial drugs face the problem of drug resistance, leading to decreased treatment efficacy and increased costs. Research on matrine alkaloids is not in-depth enough, the activity evaluation system is incomplete, and there is a lack of novel antibacterial synergistic substances.
Novel matrine-type alkaloids SF-34 and SF-60 were prepared by a multi-step extraction and purification method, including extraction, resin elution, column chromatography and high performance liquid chromatography separation, for use in combination with polymyxin antibiotics to enhance antibacterial effects.
When matrine-type alkaloids are used in combination with polymyxin antibiotics, they significantly enhance the antibacterial activity against Gram-negative bacteria, increase the antibacterial activity against Escherichia coli by 32 times, reduce the amount of antibiotics needed, and provide an enhanced regimen for infections caused by multidrug-resistant Gram-negative bacteria.
Smart Images

Figure CN123106716A_ABST
Abstract
Description
Technical Field
[0001] This invention relates to the technical field of medicinal chemistry, specifically disclosing a matrine-type alkaloid, its preparation method, and its application in the preparation of antibacterial synergists, particularly its application in synergistic anti-Gram-negative bacteria activity with polymyxin antibiotics. Background Technology
[0002] With the increasing prevalence of antimicrobial resistance, the treatment of bacterial infections faces significant challenges, leading to decreased clinical efficacy and increased treatment costs. There is an urgent clinical need for novel antimicrobial synergists to restore the activity of existing antibiotics. Plant-derived natural products, due to their structural diversity and biological activity, have always been an important resource for antimicrobial drug development.
[0003] *Sophora flavescens* Aiton, a plant belonging to the genus *Sophora* in the family Fabaceae, is widely distributed in northern my country. As a traditional Chinese medicine, *Sophora flavescens* and its preparations are mainly used clinically to treat infectious diseases, including skin infections, respiratory infections, and urinary tract infections. Modern pharmacological studies have found that matrine alkaloids are an important material basis for the antibacterial activity of this plant. Recent studies have shown that matrine and its derivatives can significantly enhance the antibacterial effect when used in combination with conventional antibacterial drugs, exhibiting potential antibacterial synergistic effects. However, systematic research on the active alkaloids in *Sophora flavescens* is still insufficient, the types of compounds are relatively limited, and the activity evaluation system needs further improvement. Therefore, *Sophora flavescens* and its main alkaloids deserve further in-depth research in order to discover novel, structurally significant, and synergistically potent antibacterial lead compounds. Summary of the Invention
[0004] To overcome the shortcomings of existing technologies, this invention provides a novel matrine-type alkaloid, its preparation method, and its application in the preparation of antibacterial synergists. The novel matrine-type alkaloid exhibits excellent antibacterial synergistic effects, solving the technical problems of poor antibacterial efficacy of existing antibiotics and insufficient synergistic activity of natural products.
[0005] To achieve the above objectives, the present invention provides the following technical solution:
[0006] The primary objective of this invention is to provide a matrine-type alkaloid, named SF-34 and SF-60 respectively, both with the molecular formula C. 30 H 46 N4O2 is a dimer structure of bismatrine monomers linked by C-9 and C-9' bonds; it has the structures shown in Formula I and Formula II: Formula I, Formula II.
[0007] The second objective of this invention is to provide a method for preparing matrine-type alkaloids, specifically comprising the following steps:
[0008] S1. Extraction: Sophora flavescens root powder was extracted with 95% ethanol. The extract was concentrated to obtain total extract. The total extract was dispersed in water and the pH was adjusted to 4-5. After stirring, it was allowed to stand to remove insoluble matter. Chloroform was added for extraction. The organic layer was collected and the solvent was removed to obtain total alkaloids of Sophora flavescens.
[0009] S2. Purification: The total alkaloids of Sophora flavescens were sequentially eluted with D101 macroporous resin gradient, separated by silica gel column chromatography, ODS reversed-phase column chromatography, and preparative high-performance liquid chromatography to obtain pure SF-34 and SF-60.
[0010] Preferably, the gradient elution step of D101 macroporous resin in step S2 is as follows: the total alkaloids of Materia Medica are dissolved in methanol and eluted in a pre-activated D101 macroporous resin column. Polar impurities are first washed away with pure water, and then eluted sequentially with ethanol:water volume ratios of 30:70, 50:50, and 70:30. The gradient components are collected and named resin components 1 to 4.
[0011] Preferably, the silica gel column chromatography step S2 is as follows: resin components 1-4 are subjected to silica gel column chromatography respectively, and gradient elution is performed using petroleum ether:ethyl acetate volume ratios of 70:30, 50:50, and 30:70 to obtain silica gel column components 1 to 4.
[0012] Preferably, the ODS reversed-phase column chromatography step S2 is as follows: the silica gel column fraction is subjected to ODS reversed-phase column chromatography, and gradient elution is performed using methanol:water volume ratios of 20:80, 50:50, and 80:20 as the mobile phase, and each fraction is collected.
[0013] Preferably, the preparative high performance liquid chromatography separation step S2 is as follows: each component is separated by preparative high performance liquid chromatography C18 reversed-phase column, with methanol:water at a ratio of 50:50 as the mobile phase, a flow rate of 6 mL / min, and chromatographic peaks with retention times of approximately 55-70 min are collected to obtain the matrine-type alkaloids SF-34 and SF-60.
[0014] The third objective of this invention is to provide the application of the above-mentioned matrine-type alkaloids in the preparation of antibacterial drug synergists. Studies have found that matrine-type alkaloids with the structures shown in Formula I and Formula II have no obvious antibacterial activity when used alone, but when used in combination with commonly used clinical antibacterial drugs, they can significantly enhance the antibacterial activity of the antibacterial drugs and have excellent antibacterial synergistic effects.
[0015] Preferably, the antibacterial drug is a polymyxin antibiotic.
[0016] More preferably, the antibacterial drug is colistin.
[0017] Preferably, the antibacterial agent targets Gram-negative pathogens such as Escherichia coli.
[0018] Experiments show that the matrine-type alkaloids, when used in combination with polymyxin antibiotics, enhance the antibacterial activity against Gram-negative bacteria such as Escherichia coli by up to 32 times; the fractional inhibitory concentration index (FICI) is ≤0.5, meeting the synergistic effect standard.
[0019] A fourth objective of this invention is to provide an antibacterial pharmaceutical composition comprising any one or two of the structures shown in Formula I and Formula II, matrine-type alkaloids, polymyxin antibiotics, and pharmaceutically acceptable excipients.
[0020] Preferably, the drug can be formulated into powder, pill, tablet, capsule, oral liquid, aerosol or injection, etc., according to the needs of the application scenario.
[0021] Preferably, the drug can be used to treat Gram-negative bacterial infections.
[0022] Compared with the prior art, the beneficial effects of the present invention are:
[0023] This invention provides a novel matrine-type alkaloid with a novel structure. Experiments show that matrine-type alkaloids with the structures shown in Formulas I and II do not exhibit significant antibacterial activity when used alone, but they possess excellent antibacterial synergistic effects, especially when combined with polymyxin antibiotics against Gram-negative pathogens such as Escherichia coli. The antibacterial activity against Escherichia coli is increased by 32 times, significantly reducing antibiotic dosage. This provides a novel synergistic approach for infections caused by multidrug-resistant Gram-negative bacteria and has high clinical application value. Attached Figure Description
[0024] Figure 1 The photon spectrum (600 M, CD3OD) of compound SF-34 is shown.
[0025] Figure 2 The carbon spectrum (150 M, CD3OD) of compound SF-34 is shown.
[0026] Figure 3 For compound SF-34 1 H- 1 H COSY spectrum.
[0027] Figure 4 This is the HSQC spectrum of compound SF-34.
[0028] Figure 5 This is the HMBC spectrum of compound SF-34.
[0029] Figure 6 The photon spectrum (600 M, CD3OD) of compound SF-60 is shown.
[0030] Figure 7 The carbon spectrum (150 M, CD3OD) of compound SF-60 is shown.
[0031] Figure 8 For compound SF-60 1 H- 1 H COSY spectrum.
[0032] Figure 9 The image shows the HSQC spectrum of compound SF-60.
[0033] Figure 10 The image shows the HMBC spectrum of compound SF-60.
[0034] Figure 11 The diagram shows the structural designations of compounds SF-34 and SF-60. Detailed Implementation
[0035] The technical solution of the present invention will be clearly and completely described below with reference to the embodiments of the present invention. Obviously, the described embodiments are only some embodiments of the present invention, and not all embodiments. Based on the embodiments of the present invention, all other embodiments obtained by those of ordinary skill in the art without creative effort are within the scope of protection of the present invention.
[0036] Unless otherwise specified, the experimental methods used in the embodiments of this invention are conventional methods; unless otherwise specified, the materials and reagents used are commercially available.
[0037] Example 1: Preparation of matrine-type alkaloids
[0038] The preparation method of matrine-type alkaloids specifically includes the following steps:
[0039] (1) Take 25 kg of dried Sophora flavescens root powder and extract it three times with 95% ethanol, each time for 6 h. Combine the extracts and concentrate them under reduced pressure until they become viscous to obtain 1.5 kg of total extract. Disperse the total extract in water and adjust the pH to 4–5 with 2% hydrochloric acid. After stirring thoroughly, let it stand to remove insoluble matter. Add chloroform for liquid-liquid extraction, collect the organic layer, remove the organic solvent, and obtain 850 g of total alkaloids of Sophora flavescens.
[0040] (2) Dissolve the total alkaloids of Materia Medica in an appropriate amount of methanol and load it into a pre-activated D101 macroporous resin column for fractional elution. First, wash away the polar impurities with pure water, and then elute sequentially with ethanol-water gradients (30:70, 50:50, 70:30 v / v). Collect each gradient fraction and name them resin fraction 1 to fraction 4.
[0041] (3) Resin components 1–4 were subjected to silica gel column chromatography, with gradient elution using petroleum ether-ethyl acetate (70:30, 50:50, 30:70 v / v) as the elution system to obtain silica gel column components 1 to 4.
[0042] (4) The silica gel column fractions were further subjected to ODS reversed-phase column chromatography, with methanol-water (20:80, 50:50, 80:20 v / v) as the mobile phase for gradient elution, and each fraction was collected.
[0043] (5) The components collected by the ODS column were separated by preparative high performance liquid chromatography (C18 reversed phase column). Methanol-water (50:50 v / v) was used as the mobile phase, the flow rate was 6 mL / min, and the chromatographic peaks with retention times of about 55–70 min were collected to obtain matrine-type alkaloids with well-defined structures, named SF-34 and SF-60.
[0044] Example 2: Structural identification of SF-34 and SF-60:
[0045] High-resolution mass spectrometry (HR-ESI-MS) gives them molecular formulas as C 30 H 46 N4O2 (SF-34), C 30 H 46 N4O2(SF-60).
[0046] like Figure 1 and 2 As shown, compound SF-34 1 H NMR spectrum and 13 C10 NMR spectra revealed two sets of skeletal features derived from matrine alkaloids: characteristic signals at the C-2 or C-10 position and at the C-2' or C-10' position, both originating from methylene groups attached to nitrogen atoms. Their chemical shifts were located at δ¹⁸ Å. c 57.3 / 59.3, δ H a 2.91, b 2.15 / δ H a 2.87, b 1.59; δ c 51.7 / 38.2, δ H a3.12, b 2.00 / δ Ha 1.47, b 1.09. Two sets of characteristic proton signals at the C-17 and C-17. positions of matrine-type alkaloids can also be observed, respectively δ c 41.6,δ H a4.40b 3.00; δ c 46.1,δ H a 3.74 b 2.86.
[0047] Compound SF-60 1 H NMR spectrum and 13 C NMR spectrum ( Figure 6 and Figure 7 The results show two sets of skeletal features derived from matrine alkaloids, with characteristic signals at the C-2 or C-10 position and the C-2' or C-10' position, both originating from methylene groups attached to nitrogen atoms. Their chemical shifts are located at δ... c 57.3 / 63.5, δ H a 2.78, b 1.93 / δ H a = 2.92, b = 1.81; δ c 50.5 / 37.6, δ H a3.23, b 2.12 / δ H a 1.79, b 1.20. Two sets of characteristic proton signals at the C-17 and C-17' positions of matrine-type alkaloids can also be observed, respectively δ c 47.1,δ H a 3.67 b 2.81; δ c 48.2,δ H a 3.52 b 3.06.
[0048] The planar structure of compound SF-34 can be confirmed by two-dimensional spectral analysis. Figure 3-5 As shown, compound SF-34 can be observed 1 H- 1 In the H COSY spectrum, H-9 is correlated with H-10' / H-9' / H-8 / H-8', and in the HMBC spectrum, H-9 is correlated with C-10' / C-9'. This indicates that the two matrine monomers are connected by bonds between C-9 and C-9'.
[0049] The planar structure of compound SF-60 can be confirmed by two-dimensional spectral analysis. Figure 8-10 As shown, compound SF-34 can be observed 1 H- 1In the H COSY spectrum, H-9 is correlated with H-10' / H-9' / H-8 / H-8', and in the HMBC spectrum, H-9 is correlated with C-10' / C-9'. This indicates that the two matrine monomers are connected by bonds between C-9 and C-9'.
[0050] The physicochemical data of compounds SF-34 and SF-60 are as follows: 1 H NMR (600 MHz, CDCl3) and 13 C NMR (150 MHz, CDCl3), see Table 1.
[0051] Table 1. Hydrogen and carbon spectral assignments of compounds SF-34 and SF-60 (CDCl3, δ in ppm, J in Hz) a
[0052] Example 3: In vitro antibacterial activity test
[0053] The in vitro antibacterial activity test of the drug combination of this invention uses a standard 96-well plate checkerboard method platform with the minimum inhibitory concentration (MIC) as the endpoint. *Escherichia coli* ATCC25922 and *Escherichia coli* MG-1655 are mainly used as representative strains.
[0054] MIC determination:
[0055] (1) Preparation of main reagents:
[0056] Mueller–Hinton broth (MHB): Dissolve an appropriate amount of MHB powder in deionized water, stir thoroughly until completely dissolved, adjust the pH to 7.2, and dilute to 1000 mL in a volumetric flask. Autoclave at 121°C for 20 min and store at 4°C. Antibiotic solution: Accurately weigh an appropriate amount of colistin antibiotic, dissolve it in sterile water to prepare a stock solution of a certain concentration, sterilize it through a 0.22 μm filter membrane, and store it at 4°C. DMSO solution: Analytical grade, sterilized through a 0.22 μm filter membrane before use.
[0057] (2) Sample preparation
[0058] Accurately weigh SF-34 and SF-60 prepared according to the method in Example 1, and prepare a 50 mM stock solution with DMSO. Before use, dilute stepwise with MHB medium to prepare working solutions of different concentrations. The final test concentrations are 100, 50, 25, 12.5, 6.25, and 3.125 μM.
[0059] (3) Cultivation and preparation of bacterial culture
[0060] Single colonies of *Escherichia coli* ATCC 25922 were inoculated into MHB medium and incubated at 37°C for 16–18 h. The overnight culture was then diluted with sterile MHB medium to adjust the bacterial suspension concentration to approximately 1 × 10⁻⁶. 6 CFU / mL, then further diluted to a final inoculum concentration of 5 × 10⁻⁶. 5 CFU / mL, for later use. Inoculate a single colony of *E. coli* MG-1655 into MHB medium and incubate at 37°C for 16–18 h; collect the overnight culture, dilute with sterile MHB medium, and adjust the bacterial suspension concentration to approximately 1 × 10⁻⁶. 6 CFU / mL, then further diluted to a final inoculum concentration of 5 × 10⁻⁶. 5 CFU / mL.
[0061] (4) Inhibition test of SF-34 and SF-60 on bacterial growth
[0062] a. Inoculate the prepared bacterial suspension into a 96-well plate at a rate of 100 μL / well;
[0063] b. Add 100 μL of SF-34 and SF-60 solutions of different concentrations to each well, with 3 replicates for each concentration. Also set up a growth control group (without drug) and a blank control group (without bacterial solution). Mix well and incubate in an incubator.
[0064] c. After incubating at 37℃ for 18 h, observe the bacterial growth in each well;
[0065] d. Observe the degree of turbidity with the naked eye or measure the absorbance (OD600 value) at a wavelength of 600 nm using an ELISA reader.
[0066] e. The lowest drug concentration that completely inhibits visible bacterial growth is defined as the minimum inhibitory concentration (MIC).
[0067] (5) Antibacterial effect test of SF-34 and SF-60 combined with colistin
[0068] a. Construct reaction systems with different concentration combinations by sequentially diluting colistin solution laterally along a 96-well plate in a 2-fold gradient and drug A solution longitudinally in a 2-fold gradient.
[0069] b. Add 100 μL of drug solution with different concentration combinations to each well, and then add 100 μL of bacterial suspension. Set up 3 replicates for each concentration combination. At the same time, set up a single drug control group (add only drug SF-34 / SF-60 or only colistin), a growth control group and a blank control group.
[0070] c. Incubate the 96-well plate in a 37°C incubator for 18 h;
[0071] d. After the culture is completed, observe the degree of turbidity with the naked eye or measure the absorbance (OD600 value) at a wavelength of 600 nm using an ELISA reader and record the bacterial growth.
[0072] e. Calculate the minimum inhibitory concentration (MIC) of drugs SF-34 / SF-60 and colistin when used alone and in combination.
[0073] (6) Result determination
[0074] The fractional inhibitory concentration index (FICI) is calculated based on the MIC values of combined drug use and single drug use. The calculation formula is as follows:
[0075] FICI = MIC (drug A in combination therapy) / MIC (drug A alone) + MIC (antibiotic in combination therapy) / MIC (antibiotic alone)
[0076] Determining drug interaction type based on FICI value:
[0077] FICI ≤ 0.5: synergistic effect; 0.5 < FICI ≤ 1: additive effect; 1 < FICI ≤ 2: irrelevant effect; FICI > 4: antagonistic effect; pharmacological experimental results are shown in Table 2.
[0078] Table 2. MIC and FIC values of colistin alone or in combination with compounds SF-34 / SF-60 against Escherichia coli.
[0079] a For compounds with a reported MIC of >512 μg / mL, use the 512 μg / mL value for FIC calculations.
[0080] As shown in Table 2, the experimental data indicate that the combined use of compounds SF-34 and SF-60 with colistin significantly reduced the MIC values of colistin against Escherichia coli ATCC25922 and MG-1655, lowering the minimum inhibitory concentration from 4 μg·mL⁻¹. −1 Reduced to 0.125 μg·mL −1 (32 times). Among them, except for the combination of SF-34 and colistin in MG-1655 with a FICI of 0.531, which belongs to the additive effect or synergistic trend according to the commonly used judgment criteria, the FICI of the other combinations were all less than 0.5, showing a synergistic effect. This indicates that the combination of compounds SF-34 and SF-60 with colistin has a significant antibacterial synergistic effect.
[0081] Obviously, the specific implementation schemes described above are merely a further detailed explanation of the purpose, technical solution and beneficial effects of the present invention. It should be understood that the above descriptions are only specific examples of the present invention and are not intended to limit the present invention. Any modifications, equivalent substitutions, improvements, etc., made within the spirit and principles of the present invention should be included within the protection scope of the present invention.
Claims
1. A matrine-type alkaloid compound, characterized in that, It has the structure shown in Equation I and Equation II: Formula I, Formula II.
2. The method for preparing a matrine-type alkaloid compound according to claim 1, characterized in that, Includes the following steps: S1. Extraction: Sophora flavescens root powder was extracted with 95% ethanol. The extract was concentrated to obtain total extract. The total extract was dispersed in water and the pH was adjusted to 4-5. After stirring, it was allowed to stand to remove insoluble matter. Chloroform was added for extraction. The organic layer was collected and the solvent was removed to obtain total alkaloids of Sophora flavescens. S2. Purification: The total alkaloids of Matrine were sequentially eluted with D101 macroporous resin gradient, separated by silica gel column chromatography, ODS reversed-phase column chromatography, and preparative high-performance liquid chromatography to obtain matrine-type alkaloids SF-34 and SF-60.
3. The preparation method according to claim 2, characterized in that, The specific process of step S2 is as follows: Dissolve the total alkaloids of *Sophora flavescens* in methanol and elute fractionally using a pre-activated D101 macroporous resin column. First, wash away polar impurities with pure water, then elute sequentially with a gradient of ethanol:water at volume ratios of 30:70, 50:50, and 70:
30. Collect each gradient fraction and name them resin fractions 1-4. Separate resin fractions 1-4 are subjected to silica gel column chromatography with a gradient elution system of petroleum ether:ethyl acetate at volume ratios of 70:30, 50:50, and 30:70 to obtain silica gel column fractions 1-4. The silica gel column fractions are then subjected to ODS reversed-phase column chromatography with a gradient elution system of methanol:water at volume ratios of 20:80, 50:50, and 80:20, collecting each fraction. Finally, each fraction is separated by preparative high-performance liquid chromatography (HPLC) using a C18 reversed-phase column with a methanol:water ratio of 50:50 as the mobile phase, a flow rate of 6 mL / min, and retention times of 55-70 seconds. The chromatographic peaks of min yielded the matrine-type alkaloids SF-34 and SF-60.
4. The application of the matrine-type alkaloid compound as described in claim 1 in the preparation of antibacterial drug synergists.
5. The application according to claim 4, characterized in that, The antibacterial drug is a polymyxin antibiotic.
6. The application according to claim 5, characterized in that, The polymyxin antibiotic is colistin.
7. The application according to claim 4, characterized in that, The antibacterial properties mentioned refer to those against Gram-negative bacteria.
8. The application according to claim 7, characterized in that, The Gram-negative bacterium mentioned is Escherichia coli.
9. An antibacterial drug composition, characterized in that, It includes any one or two of the matrine-type alkaloids with the structures shown in Formula I and Formula II as described in claim 1, polymyxin antibiotics, and pharmaceutically acceptable excipients.
10. The composition according to claim 9, characterized in that, The pharmaceutical composition formulations include powders, pills, tablets, capsules, oral liquids, aerosols, and injections.
